CA
NZ
UK
AU
IND
US
…
Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. The company was incorporated in 2016 and is based in Long Island City, New York.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -0.73M | -1.07M | -0.66M | -1.55M | -3.93M |
| Net income | -0.73M | -1.07M | -0.66M | -1.55M | -3.93M |
| Selling general administrative | 0.44M | 0.54M | 0.30M | 0.86M | 2.99M |
| Gross profit | - | - | - | - | 0.00M |
| Ebit | - | -0.80M | -0.55M | -1.52M | -3.90M |
| Ebitda | -0.60M | -0.86M | -0.61M | -1.50M | -3.91M |
| Operating income | -0.63M | -0.80M | -0.55M | -1.52M | -3.90M |
| Interest expense | 0.14M | 0.21M | 0.05M | 0.04M | 0.02M |
| Net interest income | -0.14M | -0.21M | -0.05M | -0.04M | -0.02M |
| Income tax expense | - | - | - | - | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 0.63M | 0.80M | 0.55M | 1.52M | 3.90M |
| Cost of revenue | - | - | - | - | 0.00M |
| Total other income expense net | 0.03M | -0.06M | -0.06M | 0.01M | -0.01M |
| Net income from continuing ops | -0.73M | -1.07M | -0.66M | -1.55M | -3.93M |
| Net income applicable to common shares | - | -1.07M | -0.66M | -1.55M | -3.93M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 0.00M | 0.04M | 0.06M | 0.12M | 0.20M |
| Total liab | 1.28M | 1.14M | 0.75M | 0.63M | 0.09M |
| Total stockholder equity | -1.28M | -1.10M | -0.69M | -0.51M | 0.11M |
| Other current liab | 0.36M | 0.42M | 0.18M | 0.09M | 0.04M |
| Common stock | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -9.53M | -8.80M | -7.73M | -7.07M | -5.52M |
| Cash | 0.00M | 0.04M | 0.06M | 0.07M | 0.14M |
| Total current liabilities | 1.28M | 1.14M | 0.75M | 0.63M | 0.09M |
| Net debt | 0.29M | 0.18M | 0.06M | 0.01M | - |
| Short term debt | - | - | - | 0.08M | 0.03M |
| Short long term debt | 0.29M | 0.22M | 0.12M | 0.08M | 0.03M |
| Total current assets | 0.00M | 0.04M | 0.06M | 0.12M | 0.20M |
| Net tangible assets | - | -1.10M | -0.69M | -0.51M | 0.11M |
| Accounts payable | - | 0.08M | 0.04M | 0.17M | 0.02M |
| Non currrent assets other | - | - | - | 0.00M | 0.00M |
| Non current assets total | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change to liabilities | - | 0.04M | -0.08M | 0.15M | 0.01M |
| Net borrowings | - | 0.10M | 0.11M | 0.41M | 0.41M |
| Total cash from financing activities | 0.07M | 0.10M | 0.21M | 0.47M | 0.57M |
| Change to operating activities | - | - | 0.06M | -0.00M | -0.04M |
| Net income | -0.73M | -1.07M | -0.66M | -1.55M | -3.93M |
| Change in cash | -0.03M | -0.02M | -0.01M | -0.08M | 0.09M |
| Begin period cash flow | 0.04M | 0.06M | 0.07M | 0.14M | 0.06M |
| End period cash flow | 0.00M | 0.04M | 0.06M | 0.07M | 0.14M |
| Total cash from operating activities | -0.10M | -0.12M | -0.22M | -0.55M | -0.49M |
| Issuance of capital stock | - | 0.00M | 0.10M | 0.07M | 0.57M |
| Change to netincome | - | 0.81M | 0.43M | 0.82M | 3.45M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 0.06M | 0.04M | -0.03M | 0.14M | -0.02M |
| Stock based compensation | 0.32M | 0.66M | 0.37M | 0.76M | - |
| Other non cash items | 0.28M | 0.19M | 0.20M | 0.87M | 3.46M |
| Free cash flow | -0.10M | -0.12M | -0.22M | -0.55M | -0.49M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
-0.54 1.32% |
40.55 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-2.37 0.43% |
544.66 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.77 0.29% |
956.64 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Qrons Inc., a biotechnology company, engages in development of biotech products, treatments, and technologies to combat neuronal diseases. Its product candidates include QS100, an injury specific, 3D printable, implantable mesenchymal stem cells (MSCs)-synthetic hydrogel to treat penetrating brain injuries; and QS200, an injectable MSCs-synthetic hydrogel for the treatment of concussions and other diffused axonal injuries. The company was formerly known as BioLabMart Inc. and changed its name to Qrons Inc. in August 2017. The company was incorporated in 2016 and is based in Long Island City, New York.
| Name | Title | Year Born |
|---|---|---|
| Mr. Jonah Martin Meer | Co-Founder, CEO, CFO, Sec. & Director | 1955 |
| Mr. Ido Merfeld Ph.D. | Co-Founder, Pres & Director | 1965 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.40%
Communication Services
-0.45%
Consumer Cyclical
-0.55%
Consumer Defensive
-0.01%
Energy
-0.01%
Financial Services
-0.40%
Financials
-0.15%
Healthcare
-1.15%
Industrials
-0.46%
Real Estate
-0.29%
Technology
-1.22%
Utilities
-0.10%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
+0.55%
Please wait processing your request...